News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
HilleVax, Inc. - Common Stock
(NQ:
HLVX
)
1.790
-0.020 (-1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about HilleVax, Inc. - Common Stock
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 08, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Reduction in Force
July 31, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 09, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
July 08, 2024
From
The Schall Law Firm
Via
Business Wire
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
July 08, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
March 20, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
February 05, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
January 18, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
January 08, 2024
Collaboration leverages HilleVax’s leading norovirus vaccine development expertise and adds a Phase 1-ready next-generation program to HilleVax’s pipeline
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at Upcoming Investor Conferences
November 01, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 26, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 25, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Pricing of Public Offering of Common Stock
September 19, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Proposed Public Offering of Common Stock
September 19, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 14, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 12, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
May 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
April 25, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
March 17, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Executive Management Appointments and Promotions
January 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
December 05, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Participate in November Investor Conferences
November 10, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 10, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.